Limits...
Comparative quantification of plasma TDRD7 mRNA in cataract patients by real-time polymerase chain reaction.

Kim ST, Chun JW, Park G, Koh JW - Korean J Ophthalmol (2014)

Bottom Line: After polymerase chain reaction, the results were compared after quantifying the TDRD7 mRNA using ABL1 mRNA for normalization.We analyzed the relative gene expression data via the ΔΔCt method.The comparison of the genetic values of different types of cataracts demonstrated that the TDRD7 expression level of the cortical type and mixed type were lower than those of the nuclear type and posterior subcapsular opacity type (p = 0.017).

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Chosun University College of Medicine, Gwangju, Korea.

ABSTRACT

Purpose: To investigate the relationship between plasma TDRD7 mRNA and lens transparency, and to evaluate plasma TDRD7 mRNA as a potential marker for cataracts and its sub-type by quantitatively analyzing human peripheral blood.

Methods: Plasma RNA was extracted from 40 patients with cataracts, and 30 normal controls of matched age and gender. Blood cholesterol and fasting glucose were measured, and the RNA extracted from the sample was synthesized into cDNA. After polymerase chain reaction, the results were compared after quantifying the TDRD7 mRNA using ABL1 mRNA for normalization. We analyzed the relative gene expression data via the ΔΔCt method.

Results: The normalized 2(-ΔΔCt) of plasma TDRD7 mRNA based on ABL1 mRNA was 1.52 ± 0.63 in the case of the control group and 1.05 ± 0.34 in the case of the cataract patients, and the TDRD7 expression level of the cataract patients was lower than that of the control group (p = 0.048). The comparison of the genetic values of different types of cataracts demonstrated that the TDRD7 expression level of the cortical type and mixed type were lower than those of the nuclear type and posterior subcapsular opacity type (p = 0.017).

Conclusions: Human cataracts and the TDRD7 gene loss-of-function mutations are strongly causally related, as the expression level of plasma TDRD7 mRNA in patients with cataracts was statistically significantly lower than in the normal control group.

No MeSH data available.


Related in: MedlinePlus

Normalized plasma TDRD7 mRNA in the patient group amount relative to that in normal control group. Fold change was expressed as 2-ΔΔCt (ΔCt [TDRD7-ABL1] of each case-average ΔCt [average TDRD7 Ct-average ABL1 Ct] of normal control group). Ct = cycle threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120356&req=5

Figure 2: Normalized plasma TDRD7 mRNA in the patient group amount relative to that in normal control group. Fold change was expressed as 2-ΔΔCt (ΔCt [TDRD7-ABL1] of each case-average ΔCt [average TDRD7 Ct-average ABL1 Ct] of normal control group). Ct = cycle threshold.

Mentions: The ABL1 and TDRD7 values of the control group were 26.95 ± 0.91 and 29.68 ± 1.07, respectively, and those of the cataract patients were 26.17 ± 1.25 and 29.11 ± 1.34, respectively. ΔCt was determined as the mean of the triplicate Ct values for the TDRD7 genes minus the mean of the triplicated Ct values for the ABL1 gene. ΔΔCt represented the difference between the two groups for a TDRD7 gene, more precisely ΔΔCt = ΔCt (cataract group) - ΔCt (normal group). The mean and standard deviations for all ΔCt and ΔΔCt values (cataract versus normal group) are provided in Table 2. The actual expression level of a TDRD7 gene was analyzed using the 2-ΔΔCt value. The results, including standard deviations, are listed in Table 2. As the result of adjusting the TDRD7 value in reference to ABL1 mRNA, the TDRD7 expression level of the cataract patients was found to be significantly lower than that of the control group, with a value of 1.05 ± 0.34, whereas that of the control group was 1.52 ± 0.63 (p = 0.048) (Table 2). To allow for a better overview and to show the broad spectrum of expression rates, all 2-ΔΔCt values (with standard deviations) are illustrated within a single figure (Fig. 2).


Comparative quantification of plasma TDRD7 mRNA in cataract patients by real-time polymerase chain reaction.

Kim ST, Chun JW, Park G, Koh JW - Korean J Ophthalmol (2014)

Normalized plasma TDRD7 mRNA in the patient group amount relative to that in normal control group. Fold change was expressed as 2-ΔΔCt (ΔCt [TDRD7-ABL1] of each case-average ΔCt [average TDRD7 Ct-average ABL1 Ct] of normal control group). Ct = cycle threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120356&req=5

Figure 2: Normalized plasma TDRD7 mRNA in the patient group amount relative to that in normal control group. Fold change was expressed as 2-ΔΔCt (ΔCt [TDRD7-ABL1] of each case-average ΔCt [average TDRD7 Ct-average ABL1 Ct] of normal control group). Ct = cycle threshold.
Mentions: The ABL1 and TDRD7 values of the control group were 26.95 ± 0.91 and 29.68 ± 1.07, respectively, and those of the cataract patients were 26.17 ± 1.25 and 29.11 ± 1.34, respectively. ΔCt was determined as the mean of the triplicate Ct values for the TDRD7 genes minus the mean of the triplicated Ct values for the ABL1 gene. ΔΔCt represented the difference between the two groups for a TDRD7 gene, more precisely ΔΔCt = ΔCt (cataract group) - ΔCt (normal group). The mean and standard deviations for all ΔCt and ΔΔCt values (cataract versus normal group) are provided in Table 2. The actual expression level of a TDRD7 gene was analyzed using the 2-ΔΔCt value. The results, including standard deviations, are listed in Table 2. As the result of adjusting the TDRD7 value in reference to ABL1 mRNA, the TDRD7 expression level of the cataract patients was found to be significantly lower than that of the control group, with a value of 1.05 ± 0.34, whereas that of the control group was 1.52 ± 0.63 (p = 0.048) (Table 2). To allow for a better overview and to show the broad spectrum of expression rates, all 2-ΔΔCt values (with standard deviations) are illustrated within a single figure (Fig. 2).

Bottom Line: After polymerase chain reaction, the results were compared after quantifying the TDRD7 mRNA using ABL1 mRNA for normalization.We analyzed the relative gene expression data via the ΔΔCt method.The comparison of the genetic values of different types of cataracts demonstrated that the TDRD7 expression level of the cortical type and mixed type were lower than those of the nuclear type and posterior subcapsular opacity type (p = 0.017).

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Chosun University College of Medicine, Gwangju, Korea.

ABSTRACT

Purpose: To investigate the relationship between plasma TDRD7 mRNA and lens transparency, and to evaluate plasma TDRD7 mRNA as a potential marker for cataracts and its sub-type by quantitatively analyzing human peripheral blood.

Methods: Plasma RNA was extracted from 40 patients with cataracts, and 30 normal controls of matched age and gender. Blood cholesterol and fasting glucose were measured, and the RNA extracted from the sample was synthesized into cDNA. After polymerase chain reaction, the results were compared after quantifying the TDRD7 mRNA using ABL1 mRNA for normalization. We analyzed the relative gene expression data via the ΔΔCt method.

Results: The normalized 2(-ΔΔCt) of plasma TDRD7 mRNA based on ABL1 mRNA was 1.52 ± 0.63 in the case of the control group and 1.05 ± 0.34 in the case of the cataract patients, and the TDRD7 expression level of the cataract patients was lower than that of the control group (p = 0.048). The comparison of the genetic values of different types of cataracts demonstrated that the TDRD7 expression level of the cortical type and mixed type were lower than those of the nuclear type and posterior subcapsular opacity type (p = 0.017).

Conclusions: Human cataracts and the TDRD7 gene loss-of-function mutations are strongly causally related, as the expression level of plasma TDRD7 mRNA in patients with cataracts was statistically significantly lower than in the normal control group.

No MeSH data available.


Related in: MedlinePlus